[Medical treatment of dysthyroid orbitopathy].
The majority of Graves' patients have mild and nonprogressive ocular involvement that does not require aggressive treatment. Local supportive measures such as wearing tinted lenses, proper eyelid hygiene, and the use of wetting agents or gels are usually sufficient to obtain symptomatic relief until eye disease becomes inactive. Smoking must be stopped and euthyroidism controlled. Management of severe forms (10% of patients) is often difficult and does not provide consistently favorable results. The use of glucocorticoids is a well-established method of treatment, indicated in severe inflammatory forms as well as in complicated forms of optic neuropathy, ocular hypertension, and corneal exposure, and are used orally or intravenously, at high doses and for prolonged periods of time. Prisms are useful in cases of diplopia. Favorable effects are reported in slightly more than 60% of cases. Glucocorticoids can be combined with orbital radiotherapy in patients with severe orbitopathy.
Badelon
I
I
Fondation Ophtalmologique A. De Rottschild, 25-29 rue Manin, 75019 Paris.
Morax
S
S
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005139:Eyeglasses; D006111:Graves Disease / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D016540:Smoking Cessation
D000893:Anti-Inflammatory Agents; D009883:Ophthalmic Solutions; D011241:Prednisone; D008775:Methylprednisolone